- Home
- AAMI vs HCM Comparison
AAMI vs HCM Comparison
Compare AAMI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | HCM |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AAMI | HCM |
|---|---|---|
| Price | $68.58 | $12.55 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $58.00 | $13.75 |
| AVG Volume (30 Days) | ★ 286.8K | 26.3K |
| Earning Date | 04-30-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.73 | $20.60 |
| Revenue Next Year | $14.44 | $15.62 |
| P/E Ratio | $23.86 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.26 | $12.42 |
| 52 Week High | $73.10 | $19.50 |
Technical Indicators
Market Signals| Indicator | AAMI | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 27.15 |
| Support Level | $45.58 | N/A |
| Resistance Level | $69.87 | $15.75 |
| Average True Range (ATR) | 2.73 | 0.31 |
| MACD | -0.22 | -0.08 |
| Stochastic Oscillator | 57.44 | 9.85 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.